249 related articles for article (PubMed ID: 15308730)
1. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.
Diwan P; Lacasse JJ; Schang LM
J Virol; 2004 Sep; 78(17):9352-65. PubMed ID: 15308730
[TBL] [Abstract][Full Text] [Related]
2. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
Schang LM; Rosenberg A; Schaffer PA
J Virol; 2000 Mar; 74(5):2107-20. PubMed ID: 10666240
[TBL] [Abstract][Full Text] [Related]
3. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
Schang LM
Biochim Biophys Acta; 2004 Mar; 1697(1-2):197-209. PubMed ID: 15023361
[TBL] [Abstract][Full Text] [Related]
4. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.
Schang LM; Coccaro E; Lacasse JJ
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):829-37. PubMed ID: 16248044
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Schang LM; Bantly A; Knockaert M; Shaheen F; Meijer L; Malim MH; Gray NS; Schaffer PA
J Virol; 2002 Aug; 76(15):7874-82. PubMed ID: 12097601
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.
Davido DJ; Leib DA; Schaffer PA
J Virol; 2002 Feb; 76(3):1077-88. PubMed ID: 11773384
[TBL] [Abstract][Full Text] [Related]
7. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
Schang LM; Rosenberg A; Schaffer PA
J Virol; 1999 Mar; 73(3):2161-72. PubMed ID: 9971799
[TBL] [Abstract][Full Text] [Related]
8. The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.
Davido DJ; Von Zagorski WF; Maul GG; Schaffer PA
J Virol; 2003 Dec; 77(23):12603-16. PubMed ID: 14610183
[TBL] [Abstract][Full Text] [Related]
9. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
Pumfery A; de la Fuente C; Berro R; Nekhai S; Kashanchi F; Chao SH
Curr Pharm Des; 2006; 12(16):1949-61. PubMed ID: 16787240
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.
Evers DL; Breitenbach JM; Borysko KZ; Townsend LB; Drach JC
Antimicrob Agents Chemother; 2002 Aug; 46(8):2470-6. PubMed ID: 12121920
[TBL] [Abstract][Full Text] [Related]
11. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
Schang LM; St Vincent MR; Lacasse JJ
Antivir Chem Chemother; 2006; 17(6):293-320. PubMed ID: 17249245
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinases as cellular targets for antiviral drugs.
Schang LM
J Antimicrob Chemother; 2002 Dec; 50(6):779-92. PubMed ID: 12460995
[TBL] [Abstract][Full Text] [Related]
13. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
Schang LM; Phillips J; Schaffer PA
J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of transcriptional regulation of herpes simplex virus type 1 tegument protein VP22.
Yu X; Li W; Liu L; Che Y; Cun W; Wu W; He C; Shao C; Li Q
Sci China C Life Sci; 2008 Nov; 51(11):966-72. PubMed ID: 18989638
[TBL] [Abstract][Full Text] [Related]
17. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity.
Habran L; Bontems S; Di Valentin E; Sadzot-Delvaux C; Piette J
J Biol Chem; 2005 Aug; 280(32):29135-43. PubMed ID: 15955820
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.
Taylor SL; Kinchington PR; Brooks A; Moffat JF
J Virol; 2004 Mar; 78(6):2853-62. PubMed ID: 14990704
[TBL] [Abstract][Full Text] [Related]
19. Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases.
Jordan R; Schang L; Schaffer PA
J Virol; 1999 Oct; 73(10):8843-7. PubMed ID: 10482641
[TBL] [Abstract][Full Text] [Related]
20. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
Schang LM
Antivir Chem Chemother; 2001; 12 Suppl 1():157-78. PubMed ID: 11594683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
